What is B. Riley's Estimate for CAPR Q1 Earnings?

Key Points

• B. Riley analysts estimate that Capricor Therapeutics will report a Q1 2026 earnings per share (EPS) of ($0.40), maintaining a "Strong-Buy" rating on the stock.
• The company's recent quarterly earnings showed a wider loss at ($0.57) per share, missing previous estimates and reflecting a negative return on equity of 62.71%.
• Capricor Therapeutics has seen significant institutional investment, with notable increases in holdings by major investors such as Tower Research Capital, indicating strong market interest in the company.

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) - Equities research analysts at B. Riley issued their Q1 2026 EPS estimates for shares of Capricor Therapeutics in a note issued to investors on Sunday, September 14th. B. Riley analyst M. El-Saadi forecasts that the biotechnology company will post earnings of ($0.40) per share for the quarter. B. Riley currently has a "Strong-Buy" rating on the stock. The consensus estimate for Capricor Therapeutics' current full-year earnings is ($1.21) per share.

CAPR has been the topic of a number of other reports. Jones Trading decreased their price objective on Capricor Therapeutics from $40.00 to $29.00 and set a "buy" rating on the stock in a report on Wednesday, June 25th. Oppenheimer dropped their price target on shares of Capricor Therapeutics from $43.00 to $22.00 and set an "outperform" rating on the stock in a research note on Monday, June 23rd. Roth Capital lowered their target price on shares of Capricor Therapeutics from $31.00 to $12.00 and set a "buy" rating on the stock in a report on Monday, July 14th. HC Wainwright reissued a "buy" rating and issued a $24.00 price objective on shares of Capricor Therapeutics in a research report on Thursday, September 11th. Finally, Alliance Global Partners reissued a "buy" rating on shares of Capricor Therapeutics in a report on Monday, July 14th. One investment analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $22.56.

Capricor Therapeutics Stock Up 3.9%

CAPR stock traded up $0.25 during midday trading on Wednesday, hitting $6.65. The company's stock had a trading volume of 1,851,794 shares, compared to its average volume of 1,069,122. Capricor Therapeutics has a 1 year low of $4.93 and a 1 year high of $23.40. The stock's 50-day moving average price is $7.01 and its 200 day moving average price is $9.55. The stock has a market cap of $304.02 million, a price-to-earnings ratio of -4.05 and a beta of 0.73.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its earnings results on Monday, August 11th. The biotechnology company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.09). Capricor Therapeutics had a negative net margin of 181.71% and a negative return on equity of 62.71%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Krilogy Financial LLC boosted its position in shares of Capricor Therapeutics by 9.6% during the 1st quarter. Krilogy Financial LLC now owns 22,800 shares of the biotechnology company's stock valued at $216,000 after purchasing an additional 2,000 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Capricor Therapeutics by 2.1% in the first quarter. Charles Schwab Investment Management Inc. now owns 113,650 shares of the biotechnology company's stock valued at $1,079,000 after acquiring an additional 2,314 shares during the last quarter. Deutsche Bank AG lifted its position in shares of Capricor Therapeutics by 10.9% in the first quarter. Deutsche Bank AG now owns 28,699 shares of the biotechnology company's stock worth $272,000 after buying an additional 2,822 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Capricor Therapeutics by 31.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,246 shares of the biotechnology company's stock valued at $126,000 after purchasing an additional 3,162 shares during the period. Finally, Legal & General Group Plc increased its stake in shares of Capricor Therapeutics by 8.4% in the second quarter. Legal & General Group Plc now owns 41,273 shares of the biotechnology company's stock worth $410,000 after purchasing an additional 3,205 shares during the period. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.